Navigation Links
Vaccine may double survival in patients with deadly brain tumors
Date:6/2/2008

DURHAM, N.C. -- A vaccine aimed at inducing immunity to the most common and deadly type of brain tumor may stave off recurrence and more than double survival in patients, according to a new study led by researchers in Dukes Preston Robert Tisch Brain Tumor Center.

This vaccine represents a very promising therapy for a cancer that comes out of the blue and robs people of something most of us take for granted -- time, said John Sampson, M.D., Ph.D., a neurosurgeon at Duke and lead investigator on this study. The possibility of doubling expected survival -- with few if any side effects -- would represent a big step and a lot of hope for this group of patients.

Sampson presented the results of this Phase II study during an oral presentation at the annual American Society of Clinical Oncology meeting in Chicago on June 2, 2008. The study was funded by the National Institutes of Health and Celldex Therapeutics, a subsidiary of Avant Immunotherapeutics, which has licensed the rights to the vaccine and provided vaccine for use in the study.

The vaccine targets a protein expressed on about half of all glioblastoma multiforme (GBM) tumors. The protein, known as epithelial growth factor receptor variant III (EGFRvIII), is not expressed in normal tissues but is prevalent in GBMs, which makes it an attractive target for a vaccine, Sampson said.

The vaccine targets the protein and enhances immune response to it, killing tumor cells that express the protein and preventing the re-growth of brain tumors in patients who have already been diagnosed and treated with standard regimens including surgery, chemotherapy and radiation.

This study included 23 patients, treated at Duke and at M.D. Anderson Cancer Center. Patients had all been diagnosed with GBMs, and had been treated with standard therapy. Patients in the trial received vaccine injections monthly and were given a chemotherapeutic agent called temozolomide in conjunction with th
'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...e-FirstCall/ -- The Providence Service,Corporatio...Norris, the Company,s,Chief Operating Officer, ha...ors. Mr. Norris, appointment fills the vacancy le...inger and returns the board to six members. Mr.,...d. , Mr. Norris, age 41, has been with Prov...
(Date:11/21/2008)...ovel technique to combat cancer, study says, ,...lgian researchers have discovered that some cancer...and this might lead to new treatments that starve ...ate, all cells in the body need to produce energy....s that requires oxygen. Compared with normal cells...
(Date:11/21/2008)...rously Protect Investment And Restore Shareholder ...SNewswire/ -- Dr. Stephen Joffe, Craig Joffe, and ...dule 13D with the U.S. Securities and Exchange Com...ing ownership of 11.4% of LCA-Vision, Inc. (Nasdaq... laser vision correction centers in 33 states in t...
(Date:11/21/2008)...re-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:...rwhelmingly approved the proposals submitted to th...rmaceuticals Industries Ltd. (Nasdaq: TEVA ). ,...ing support of the transaction by the Barr shareho...CEO. "We are pleased with the progress that we con...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
...staurants and the flourishing livestock trade in B...ng the sale of beef and pork following an outbreak...tan government spokesperson said cases of the cont...pecies of cloven-hoofed animals were being reporte...
...ientists in the US have solved the structure of a ...ing that they say will help treat cardiac or neuro...r researchers at Brown University have solved the ...ein 97 (SAP97) found in abundance in the heart and...
...lignant mesothelioma is a very aggressive tumor wh...hich is increasing in frequency throughout the wor...of Malignant mesothelioma is exposure to asbestos,...40) is also found to be a causative agent for deve...
...udies in the past have shown that certain compound... growth of breast, prostate, colon and stomach can...bladder cancer. In a more recent study researchers... hindered the growth of bladder cancer cells in th...
Other Medicine News:Health News:Malignant Mesothelioma – A New Genetic Revelatio 2Health News:Malignant Mesothelioma – A New Genetic Revelatio 3
(Date:11/19/2008)...if., Nov. 19 Amgen,(Nas...Company, a subsidiary of,Takeda Pharmaceutical Co...nrollment in the Phase 3 MONET1 trial evaluating m... and carboplatin for the first-line treatment of,...en temporarily suspended,following a planned safe...
(Date:11/19/2008)...on Payment from Roche- , , MONTVALE, N.J., ...ticals Corp. (Nasdaq: MEMY ) today announced tha...e 2 trial of R3487/MEM 3454, its lead alpha-7 nico...sociated with schizophrenia (CIAS). The Company h...riggering a $5.0 million payment from its partner ...
(Date:11/18/2008)...ciation,s 2008 Faces of Influenza survey underscor...inst influenza; Mother and Gold Medalist Kristi Ya...ov. 18 While 78 percent of mothers...and potentially life-threatening disease that can ...milies will get vaccinated this season, according ...
(Date:11/12/2008)... 12 A new study being,p...ill help answer the,question, what causes Parkinso...in the medical research into,Parkinson,s disease i...die,in the first place. Answering this question ha...nearly identical types of brain cells that produce...
Breaking Medicine Technology:Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6A Window Into Parkinson's Disease 2Interleukin Genetics Announces Conversion of 242 04 Million of Debt Into Common Stock 2307 1Interleukin Genetics Announces Conversion of 242 04 Million of Debt Into Common Stock 2307 2Interleukin Genetics Announces Conversion of 242 04 Million of Debt Into Common Stock 2307 3Jingle bells not merry for tone deaf individuals 1679 1Jingle bells not merry for tone deaf individuals 1679 2Jingle bells not merry for tone deaf individuals 1679 3Drug aimed at 2 bioterror agents blocks live viral infection Weill Cornell team reports 1676 1Drug aimed at 2 bioterror agents blocks live viral infection Weill Cornell team reports 1676 2Drug aimed at 2 bioterror agents blocks live viral infection Weill Cornell team reports 1676 3St Jude finds link between cellular defense processes showing how cancer cells survive 8556 1St Jude finds link between cellular defense processes showing how cancer cells survive 8556 2St Jude finds link between cellular defense processes showing how cancer cells survive 8556 3
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: